



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

November 15, 2024

Michael W. Kalb  
EVP and Chief Financial Officer  
CATALYST PHARMACEUTICALS, INC.  
355 Alhambra Circle  
Suite 801  
Coral Gables, FL 33134

**Re: CATALYST PHARMACEUTICALS, INC.**  
**Form 10-Q for the period ending June 30, 2024**  
**Filed August 7, 2024**  
**Form 8-K filed February 29, 2024**  
**File No. 001-33057**

Dear Michael W. Kalb:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences